S. Chevaliez, M. Bouvier-alias, R. Brillet, and J. Pawlotsky, Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, vol.44, issue.1, pp.22-31, 2007.
DOI : 10.1002/hep.21656

S. Chevaliez, M. Bouvier-alias, S. Laperche, C. Hezode, and J. Pawlotsky, Performance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification, Journal of Clinical Microbiology, vol.48, issue.10, pp.3641-3648, 2010.
DOI : 10.1128/JCM.01306-10

URL : https://hal.archives-ouvertes.fr/inserm-00529803

S. Chevaliez, M. Bouvier-alias, and J. Pawlotsky, Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification, Journal of Clinical Microbiology, vol.47, issue.6, pp.1726-1758, 2009.
DOI : 10.1128/JCM.01300-08

URL : https://hal.archives-ouvertes.fr/inserm-00395281

J. Vermehren, G. Colucci, P. Gohl, N. Hamdi, A. Abdelaziz et al., Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity, Journal of Clinical Microbiology, vol.49, issue.9, pp.3309-3324, 2011.
DOI : 10.1128/JCM.00602-11

M. Ghany, D. Nelson, D. Strader, D. Thomas, and L. Seeff, An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases, Hepatology, vol.54, issue.suppl 1, pp.1433-1477, 2011.
DOI : 10.1002/hep.24641

M. Ghany, D. Strader, D. Thomas, and L. Seeff, Diagnosis, management, and treatment of hepatitis C: An update, Hepatology, vol.11, issue.Suppl 5, pp.1335-74, 2009.
DOI : 10.1002/hep.22759

Y. Liaw, N. Leung, J. Kao, T. Piratvisuth, E. Gane et al., Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatology International, vol.47, issue.Suppl 1, pp.263-283, 2008.
DOI : 10.1007/s12072-008-9080-3

A. Lok and B. Mcmahon, Chronic hepatitis B: Update 2009, Hepatology, vol.57, issue.RR-8, pp.661-663, 2009.
DOI : 10.1002/hep.23190

E. Lawitz, F. Poordad, J. Bronowicki, P. Marcellin, V. Feinman et al., The effect of using lower limit of quantitation (LLQ) vs lower limit of detection (LLD) for the definition of undetectable HCV RNA: data from the RESPOND-2 and SPRINT-2 trials, Hepatology, vol.54, p.442, 2011.

P. Harrington, W. Zeng, and L. Naeger, Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment, Hepatology, vol.5, issue.4, 2012.
DOI : 10.1002/hep.24791

M. Brunetto, F. Moriconi, F. Bonino, G. Lau, P. Farci et al., Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Hepatology, vol.102, issue.Suppl, pp.1141-50, 2009.
DOI : 10.1002/hep.22760

R. Moucari, V. Mackiewicz, O. Lada, M. Ripault, C. Castelnau et al., Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, vol.37, issue.Suppl 2, pp.1151-1158, 2009.
DOI : 10.1002/hep.22744

K. Wursthorn, M. Jung, A. Riva, Z. Goodman, P. Lopez et al., Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients, Hepatology, vol.99, issue.Suppl. 1, pp.1611-1631, 2010.
DOI : 10.1002/hep.23905

H. Chan, A. Thompson, M. Martinot-peignoux, T. Piratvisuth, M. Cornberg et al., Hepatitis B surface antigen quantification: Why and how to use it in 2011 ??? A core group report, Journal of Hepatology, vol.55, issue.5, pp.1121-1152, 2011.
DOI : 10.1016/j.jhep.2011.06.006

H. Janssen, A comparison of two assays for quantification of Hepatitis B surface antigen in patients with chronic hepatitis B, J Clin Virol, vol.51, pp.175-183, 2011.

M. Miedouge, K. Saune, N. Kamar, M. Rieu, L. Rostaing et al., Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients, Journal of Clinical Virology, vol.48, issue.1, pp.18-21, 2010.
DOI : 10.1016/j.jcv.2010.02.012

R. Ross, S. Viazov, S. Salloum, P. Hilgard, G. Gerken et al., Analytical Performance Characteristics and Clinical Utility of a Novel Assay for Total Hepatitis C Virus Core Antigen Quantification, Journal of Clinical Microbiology, vol.48, issue.4, pp.1161-1169, 2010.
DOI : 10.1128/JCM.01640-09

R. Jardi, F. Rodriguez-frias, M. Buti, M. Schaper, A. Valdes et al., Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA, Hepatology, vol.126, issue.1, pp.133-142, 2004.
DOI : 10.1002/hep.20275

E. Tuaillon, A. Mondain, F. Meroueh, L. Ottomani, M. Picot et al., Dried blood spot for hepatitis C virus serology and molecular testing, Hepatology, vol.68, pp.752-760, 2010.
DOI : 10.1002/hep.23407

A. Marconi, M. Balestrieri, G. Comastri, F. Pulvirenti, W. Gennari et al., Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens, Clinical Microbiology and Infection, vol.15, issue.1, pp.93-100, 2009.
DOI : 10.1111/j.1469-0691.2008.02116.x

W. Wang, B. Barratt, D. Clayton, and J. Todd, Genome-wide association studies: theoretical and practical concerns, Nature Reviews Genetics, vol.60, issue.2, pp.109-127, 2005.
DOI : 10.1093/jnci/djh075

J. Hardy and A. Singleton, Genomewide Association Studies and Human Disease, New England Journal of Medicine, vol.360, issue.17, pp.1759-68, 2009.
DOI : 10.1056/NEJMra0808700

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422859

C. Ku, E. Loy, Y. Pawitan, and K. Chia, The pursuit of genome-wide association studies: where are we now?, Journal of Human Genetics, vol.461, issue.4, pp.195-206, 2010.
DOI : 10.1038/jhg.2010.19

Z. Wang, M. Gerstein, and M. Snyder, RNA-Seq: a revolutionary tool for transcriptomics, Nature Reviews Genetics, vol.328, issue.1, pp.57-63, 2009.
DOI : 10.1038/nrg2484

M. Metzker, Sequencing technologies ??? the next generation, Nature Reviews Genetics, vol.37, issue.1, pp.31-46, 2010.
DOI : 10.1038/nrg2626

S. Bennett, . Solexa, and . Ltd, Solexa Ltd, Pharmacogenomics, vol.5, issue.4, pp.433-441, 2004.
DOI : 10.1517/14622416.5.4.433

M. Margulies, M. Egholm, W. Altman, S. Attiya, J. Bader et al., Genome sequencing in microfabricated high-density picolitre reactors, Nature, vol.2, pp.376-80, 2005.
DOI : 10.1016/0888-7543(88)90007-9

J. Branciforte, I. Stoner, S. Cawley, M. Lyons, Y. Fu et al., An integrated semiconductor device enabling non-optical genome sequencing, Nature, vol.475, pp.348-52, 2011.

J. Sorenson, A. Tomaney, K. Travers, M. Trulson, J. Vieceli et al., Real-time DNA sequencing from single polymerase molecules, Science, vol.323, pp.133-141, 2009.

O. Harismendy, P. Ng, R. Strausberg, X. Wang, T. Stockwell et al., Evaluation of next generation sequencing platforms for population targeted sequencing studies, Genome Biology, vol.10, issue.3, p.32, 2009.
DOI : 10.1186/gb-2009-10-3-r32

Y. Shen, S. Sarin, Y. Liu, and O. Hobert, Comparing Platforms for C. elegans Mutant Identification Using High-Throughput Whole-Genome Sequencing, PLoS ONE, vol.452, issue.12, p.4012, 2008.
DOI : 10.1371/journal.pone.0004012.t006

N. Walter, D. Bottomly, T. Laderas, M. Mooney, P. Darakjian et al., High throughput sequencing in mice: a platform comparison identifies a preponderance of cryptic SNPs, BMC Genomics, vol.10, issue.1, p.379, 2009.
DOI : 10.1186/1471-2164-10-379

S. Suzuki, N. Ono, C. Furusawa, B. Ying, and T. Yomo, Comparison of Sequence Reads Obtained from Three Next-Generation Sequencing Platforms, PLoS ONE, vol.5, issue.5, p.19534, 2011.
DOI : 10.1371/journal.pone.0019534.s003

J. Dohm, C. Lottaz, T. Borodina, and H. Himmelbauer, Substantial biases in ultra-short read data sets from high-throughput DNA sequencing, Nucleic Acids Research, vol.36, issue.16, p.105, 2008.
DOI : 10.1093/nar/gkn425

N. Hoppman-chaney, L. Peterson, E. Klee, S. Middha, L. Courteau et al., Evaluation of Oligonucleotide Sequence Capture Arrays and Comparison of Next-Generation Sequencing Platforms for Use in Molecular Diagnostics, Clinical Chemistry, vol.56, issue.8, pp.1297-306, 2010.
DOI : 10.1373/clinchem.2010.145441

A. Gilles, E. Meglecz, N. Pech, S. Ferreira, T. Malausa et al., Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing, BMC Genomics, vol.23, issue.21, p.245, 2011.
DOI : 10.1093/bioinformatics/btm404

B. Ewing and P. Green, II. Error Probabilities, Genome Research, vol.8, issue.3, pp.186-94, 1998.
DOI : 10.1101/gr.8.3.186

B. Ewing, L. Hillier, M. Wendl, and P. Green, ???I. Accuracy???Assessment, Genome Research, vol.8, issue.3, pp.175-85, 1998.
DOI : 10.1101/gr.8.3.175

P. Richterich, Estimation of Errors in ???Raw??? DNA Sequences: A Validation???Study, Genome Research, vol.8, issue.3
DOI : 10.1101/gr.8.3.251

B. Richter and D. Sexton, Managing and Analyzing Next-Generation Sequence Data, PLoS Computational Biology, vol.5, issue.6
DOI : 10.1371/journal.pcbi.1000369

URL : http://doi.org/10.1371/journal.pcbi.1000369

C. Wang, Y. Mitsuya, B. Gharizadeh, M. Ronaghi, and R. Shafer, Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance, Genome Research, vol.17, issue.8, pp.1195-201, 2007.
DOI : 10.1101/gr.6468307

J. Archer, A. Rambaut, B. Taillon, P. Harrigan, M. Lewis et al., The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time???An Ultra-Deep Approach, PLoS Computational Biology, vol.54, issue.12, p.1001022, 2010.
DOI : 10.1371/journal.pcbi.1001022.s001

A. Poon, L. Swenson, W. Dong, W. Deng, K. Pond et al., Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1, Molecular Biology and Evolution, vol.27, issue.4, pp.819-851, 2010.
DOI : 10.1093/molbev/msp289

S. Gianella, W. Delport, M. Pacold, J. Young, J. Choi et al., Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants, Journal of Virology, vol.85, issue.16, pp.8359-67, 2011.
DOI : 10.1128/JVI.02582-10

C. Rodriguez, C. Chevaliez, P. Bensadoun, and J. Pawlotsky, Ultra-deep pyrosequencing, a powerful new tool to study HBV Resistance to nucleoside/nucleotide analogues, identifies pre-existing HBV variants bearing resistance mutations and characterizes their on-treatment kinetics, Hepatology, vol.52, p.117, 2011.

S. Chevaliez, C. Rodriguez, A. Soulier, A. Ahmed-belkacem, C. Hezode et al., 67 MOLECULAR CHARACTERIZATION OF HCV RESISTANCE TO TELAPREVIR BY MEANS OF ULTRA-DEEP PYROSEQUENCING: PREEXISTING RESISTANT VARIANTS AND DYNAMICS OF RESISTANT POPULATIONS, Journal of Hepatology, vol.54, p.30, 2011.
DOI : 10.1016/S0168-8278(11)60069-X

C. Rodriguez, C. Soulie, A. Marcelin, V. Calvez, D. Descamps et al., HIV-1 coreceptor usage prediction by " ultra-deep pyrosequencing " increases the rate of patients treated with success by CCR5 antagonists, Antiviral Ther, vol.16, p.100, 2011.

C. Chen, W. Lee, H. Yang, H. Chang, C. Jen et al., Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma, Gastroenterology, vol.141, issue.4, pp.1240-1248, 2011.
DOI : 10.1053/j.gastro.2011.06.036

C. Chen, H. Yang, and U. Iloeje, Hepatitis B virus DNA levels and outcomes in chronic hepatitis B, Hepatology, vol.48, issue.S5, pp.72-84, 2009.
DOI : 10.1002/hep.22884

E. Buster and H. Janssen, The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued, Journal of Hepatology, vol.54, issue.2, pp.395-401, 2011.
DOI : 10.1016/j.jhep.2010.07.052

S. Raimondi, P. Maisonneuve, S. Bruno, and M. Mondelli, Is response to antiviral treatment influenced by hepatitis B virus genotype?, Journal of Hepatology, vol.52, issue.3, pp.441-450, 2010.
DOI : 10.1016/j.jhep.2009.12.014

G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman et al., Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses, Gastroenterology, vol.139, issue.4, pp.1218-1247, 2010.
DOI : 10.1053/j.gastro.2010.06.042

R. Zoutendijk, J. Reijnders, A. Brown, F. Zoulim, D. Mutimer et al., Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of na??ve patients with a partial virological response, Hepatology, vol.49, issue.5 Suppl., pp.443-51, 2011.
DOI : 10.1002/hep.24406

J. Pawlotsky, G. Dusheiko, A. Hatzakis, D. Lau, G. Lau et al., Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach, Gastroenterology, vol.134, issue.2, pp.405-420, 2008.
DOI : 10.1053/j.gastro.2007.11.036

S. Chevaliez, M. Bouvier-alias, R. Brillet, and J. Pawlotsky, Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice, PLoS ONE, vol.4, issue.12, p.8209, 2009.
DOI : 10.1371/journal.pone.0008209.t002

URL : https://hal.archives-ouvertes.fr/inserm-00443832

P. Clark and A. Thompson, Host genomics and HCV treatment response, Journal of Gastroenterology and Hepatology, vol.364, issue.suppl. 1, pp.212-234, 2012.
DOI : 10.1111/j.1440-1746.2011.06918.x

J. Pawlotsky, Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus, Hepatology, vol.53, issue.5, pp.1742-51, 2011.
DOI : 10.1002/hep.24262

J. Sullivan, D. Meyer, S. Bartels, D. Dierynck, I. Zhang et al., 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS, Journal of Hepatology, vol.54, p.4, 2011.
DOI : 10.1016/S0168-8278(11)60010-X

. Roche-molecular and . Systems, CA Real-time PCR Manual with High Pure System Viral Nucleic Acid Kit COBAS ® TaqMan 650 ?L 20 IU/mL 25 (1.4 Log10)- 3, ) IU/mL COBAS ® Ampliprep - COBAS ® TaqMan ® (CAP/CTM) HCV Test

L. Molecular, Des Plaines, IL Real-time PCR m2000SP m2000RT 200 or 500 ?L 12 IU/mL (for 500?L) 30 IU/mL (for 200 ?L

H. Artus, *. Assay, and . Qiagen, Germany Real-time PCR QIAsymphony RGQ Rotor-Gene Q 1000 ?L 36

L. and V. Hcv-rna, Assay (kPCR) Siemens Medical Solutions Diagnostics, Tarrytown, NY Real-time PCR Sample Preparation (SP) Module Amplification and Detection (AD) Module 500 ?L 15 IU